Generate Biomedicines, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Generate Biomedicines, Inc. - overview
Established
2018
Location
Somerville, MA, US
Primary Industry
Biotechnology
About
Based in Massachusetts, US, and founded in 2018 by Molly Gibson (Co‑Founder); Gevorg Grigoryan (Co‑Founder & CTO); Noubar Afeyan (Founder & CEO), Generate Biomedicines, Inc. , formerly known as Flagship VL56, Inc. , operates as a therapeutics company that offers solutions for drug discovery and development. In May 2026, Generate Biomedicines, Inc.
raised USD 10. 4 million in PIPE funding from Nventures. The company offers a biomedicine platform that can produce new medications on demand across a wide range of biologic modalities, including short peptides, complicated antibodies, enzymes, cytokines, and protein compositions that have yet to be identified. The company uses machine learning technology for the identification and validation of targets and treatments, as well as the specificity of target engagement by produced proteins and the cost of identifying and producing clinical candidates.
Generate Biomedicines earns revenue through strategic partnerships with pharma companies, licensing its AI-driven Generative Biology™ platform, and advancing proprietary therapeutics into clinical trials. The company will use the May 2026 funding to support its growth in AI-enabled drug discovery.
Current Investors
Nventures, ARCH Venture Partners, Flagship Pioneering
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Bioinformatics, Pharmaceutical Research & Development
Website
www.generatebiomedicines.com/
Verticals
Artificial Intelligence, HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Generate Biomedicines, Inc. - financials
| Fiscal Year Ended | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|
| Revenue (USD) | - | - |
| % Revenue Growth (YoY) | - | - |
| EBITDA (USD) | - | - |
| Operating Income (USD) | - | - |
| Operating Margin | - | - |
| % EBITDA Margin | - | - |
| NET Income (USD) | - | - |
| % Net Margin | - | - |
Generate Biomedicines, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Generate Biomedicines, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.